Molecular Mechanisms and Clinical Management of Cancer Bone Metastasis

Overview

Journal Bone Res

Specialties Endocrinology
Orthopedics

Date 2020 Aug 15

PMID 32793401

Citations 61

Authors

Manni Wang

Fan Xia

Yuquan Wei

Xiawei Wei

Affiliations

Soon will be listed here.

Abstract

As one of the most common metastatic sites of malignancies, bone has a unique microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated capillaries in the bone, bone matrix, and bone cells, including osteoblasts and osteoclasts, together maintain the homeostasis of the bone microenvironment. In contrast, tumor-derived factors act on bone components, leading to subsequent bone resorption or excessive bone formation. The various pathways involved also provide multiple targets for therapeutic strategies against bone metastases. In this review, we summarize the current understanding of the mechanism of bone metastases. Based on the general process of bone metastases, we specifically highlight the complex crosstalk between tumor cells and the bone microenvironment and the current management of cancer bone metastases.

Citing Articles

Role of TRP Channels in Cancer-Induced Bone Pain.

Coluzzi F, Scerpa M, Alessandri E, Romualdi P, Rocco M Int J Mol Sci. 2025; 26(3).

PMID: 39940997 PMC: 11818569. DOI: 10.3390/ijms26031229.

Metastasis lesion segmentation from bone scintigrams using encoder-decoder architecture model with multi-attention and multi-scale learning.

Xie A, Lin Q, He Y, Zeng X, Cao Y, Man Z Quant Imaging Med Surg. 2025; 15(1):689-708.

PMID: 39839026 PMC: 11744147. DOI: 10.21037/qims-24-1246.

CRISPR/Cas9 Technology Providing the Therapeutic Landscape of Metastatic Prostate Cancer.

Park J, Kim J Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770431 PMC: 11676443. DOI: 10.3390/ph17121589.

Regulation of metastatic organotropism.

Dunbar K, Efe G, Cunningham K, Esquea E, Navaridas R, Rustgi A Trends Cancer. 2024; 11(3):216-231.

PMID: 39732596 PMC: 11903188. DOI: 10.1016/j.trecan.2024.11.012.

How the bone microenvironment shapes the pre-metastatic niche and metastasis.

Jackett K, Browne A, Aber E, Clements M, Kaplan R Nat Cancer. 2024; 5(12):1800-1814.

PMID: 39672975 DOI: 10.1038/s43018-024-00854-6.

References

Roelofs A, Thompson K, Gordon S, Rogers M . Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12(20 Pt 2):6222s-6230s. DOI: 10.1158/1078-0432.CCR-06-0843. View

Mandal C, Ghosh-Choudhury T, Yoneda T, Ghosh Choudhury G, Ghosh-Choudhury N . Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res Commun. 2010; 402(4):602-7. PMC: 2993881. DOI: 10.1016/j.bbrc.2010.10.063. View

Mao D, Epple H, Uthgenannt B, Novack D, Faccio R . PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest. 2006; 116(11):2869-79. PMC: 1616195. DOI: 10.1172/JCI28775. View

Havens A, Jung Y, Sun Y, Wang J, Shah R, Buhring H . The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer. 2006; 6:195. PMC: 1557671. DOI: 10.1186/1471-2407-6-195. View

Bendre M, Montague D, Peery T, Akel N, Gaddy D, Suva L . Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003; 33(1):28-37. DOI: 10.1016/s8756-3282(03)00086-3. View

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

Henry J, Mitnick M, Dann P, Stewart A . Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab. 1997; 82(3):900-6. DOI: 10.1210/jcem.82.3.3811. View

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A . TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res. 2014; 29(8):1886-99. DOI: 10.1002/jbmr.2215. View

10.

Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

11.

Pu R, Zhao Q, Li Z, Zhang L, Luo X, Zeren Y . Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. Oncol Lett. 2016; 12(3):2023-2027. PMC: 4998527. DOI: 10.3892/ol.2016.4879. View

12.

LeBeau A, Kostova M, Craik C, Denmeade S . Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biol Chem. 2010; 391(4):333-43. PMC: 3454521. DOI: 10.1515/BC.2010.044. View

13.

Bruni-Cardoso A, Johnson L, Vessella R, Peterson T, Lynch C . Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res. 2010; 8(4):459-70. PMC: 2946627. DOI: 10.1158/1541-7786.MCR-09-0445. View

14.

Pinilla S, Alt E, Abdul Khalek F, Jotzu C, Muehlberg F, Beckmann C . Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett. 2009; 284(1):80-5. DOI: 10.1016/j.canlet.2009.04.013. View

15.

Chen Y, Wang X, Chen G, Dong C, Zhang D . The impact of matrix metalloproteinase 2 on prognosis and clinicopathology of breast cancer patients: a systematic meta-analysis. PLoS One. 2015; 10(3):e0121404. PMC: 4376789. DOI: 10.1371/journal.pone.0121404. View

16.

Guise T . Examining the metastatic niche: targeting the microenvironment. Semin Oncol. 2010; 37 Suppl 2:S2-14. DOI: 10.1053/j.seminoncol.2010.10.007. View

17.

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

18.

Koutsilieris M, Mitsiades C, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C . Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res. 2004; 10(13):4398-405. DOI: 10.1158/1078-0432.CCR-04-0077. View

19.

Ranuncolo S, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L . Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer. 2003; 106(5):745-51. DOI: 10.1002/ijc.11288. View

20.

Hartsell W, Scott C, Bruner D, Scarantino C, Ivker R, Roach 3rd M . Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005; 97(11):798-804. DOI: 10.1093/jnci/dji139. View